Abstract:BACKGROUND:RNA methylation refers to a form of methyl modification in RNA that modulates various epigenetic alterations. Mounting studies have focused on its potential mechanisms in cancer initiation and progression. However, the prognostic value and potential role of RNA methylation in the immune microenvironment of pancreatic cancer remain unclear.METHODS:Comprehensive bioinformatics analysis was performed to illuminate the expression profiles of RNA methylation modulators. In addition, the ConsensusClusterPlus algorithm was utilized to identify two remarkably different subtypes, and a feasible risk stratification method was established to accurately estimate prognosis. In addition, we validated our signature at the cytology and histology levels and conducted functional experiments to explore the biological functions of our key genes.RESULTS:Two subtypes with remarkable survival differences were identified by the consensus clustering algorithm. Cluster 2 tended to have higher expression levels of RNA methylation regulators and to be the high RNA methylation group. In addition, cluster 1 exhibited a significantly higher abundance of almost all immune cells and increased immune checkpoint expression compared to cluster 2. Chemotherapeutic sensitivity analysis indicated that there were significant differences in the sensitivity of four of the six drugs between different subgroups. Mutation investigation revealed a higher mutation burden and a higher number of mutations in cluster 2. An accurate and feasible risk stratification method was established based on the expression of key genes of each subtype. Patients with low risk scores exhibited longer survival times in one training (TCGA) and two validation cohorts (ICGC, GSE57495), with p values of 0.001, 0.0081, and 0.0042, respectively. In addition, our signature was further validated in a cohort from Fudan University Shanghai Cancer Center. The low-risk group exhibited higher immune cell abundance and immune checkpoint levels than the high-risk group. The characteristics of the low-risk group were consistent with those of cluster 1: higher stromal score, estimate score, and immune score and lower tumor purity. Additionally, cell function investigations suggested that knockdown of CDKN3 remarkably inhibited the proliferation and migration of pancreatic cancer cells.CONCLUSIONS:RNA methylation has a close correlation with prognosis, immune infiltration and therapy in pancreatic cancer. Our subtypes and risk stratification method can accurately predict prognosis and the efficacy of immune therapy and chemotherapy.

Using integrated analysis from multicentre studies to identify RNA methylation-related lncRNA risk stratification systems for glioma

The Methylation Modification of M6a Regulators Contributes to the Prognosis of Head and Neck Squamous Cell Carcinoma

Analysis of Microarray Data on Gene Expression and Methylation to Identify Long Non-coding RNAs in Non-small Cell Lung Cancer

Effects of RNA Methylation N6-methyladenosine Regulators on Malignant Progression and Prognosis of Melanoma.

The Potential Value of M6a RNA Methylation in the Development of Cancers Focus on Malignant Glioma

Insights into the regulatory role of RNA methylation modifications in glioma

An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma

Characterization of the m6A/m1A/m5C/m7G‐related regulators on the prognosis and immune microenvironment of glioma by integrated analysis of scRNA‐seq and bulk RNA‐seq data

The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma

Expression patterns and prognostic role of m6A RNA methylation regulators in Non-small Cell Lung Cancer

N6-methyladenosine Related Gene Expression Signatures for Predicting the Overall Survival and Immune Responses of Patients with Colorectal Cancer

RNA N1-methyladenosine regulator-mediated methylation modification patterns and heterogeneous signatures in glioma

Unveiling the role of RNA methylation in glioma: Mechanisms, prognostic biomarkers, and therapeutic targets

Prognosis Analysis and Validation of m6A Signature and Tumor Immune Microenvironment in Glioma

Integrated analysis of methylation and transcriptome identifies a novel risk model for diagnosis, prognosis, and immune characteristics in head and neck squamous cell carcinoma

Identification of M5c regulator-medicated methylation modification patterns for prognosis and immune microenvironment in glioma

Identification of RNA methylation-related lncRNAs for prognostic assessment and immunotherapy in bladder cancer—based on single cell/Bulk RNA sequencing data

Comprehensive Analysis of the Prognosis and Immune Infiltration Landscape of RNA Methylation-Related Subtypes in Pancreatic Cancer

Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation

The Identification of Critical m6A RNA Methylation Regulators as Malignant Prognosis Factors in Prostate Adenocarcinoma

The Prognostic Value and Immune Landscapes of a m6A/m5C/m1A-Related LncRNAs Signature in Head and Neck Squamous Cell Carcinoma